ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell-Dependent Tumor Immunity and Synergizes with PD-1 Blockade.

Cancer Immunol Res · 2025 · PMC12670079 · PMID 40928366

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

At the tested doses, the combination treatment showed a trend toward a superior effect ( Fig. 7C and at a higher PD-1 dose in Supplementary Fig.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.